SG11202105465WA - 2-fluorinated bile acids for the treatment of neurodegenerative diseases - Google Patents
2-fluorinated bile acids for the treatment of neurodegenerative diseasesInfo
- Publication number
- SG11202105465WA SG11202105465WA SG11202105465WA SG11202105465WA SG11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- general formula
- dihydroxy
- difluoro
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105465WA true SG11202105465WA (en) | 2021-06-29 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105465WA SG11202105465WA (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486318A4 (en) * | 2022-03-02 | 2026-02-25 | Boyce Thompson Institute For Plant Res Inc | Cysteamides, related therapeutic compositions and associated processes |
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
| GB202314563D0 (en) | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9509764A (pt) * | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| FR2934596B1 (fr) * | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| ITMI20121344A1 (it) * | 2012-07-31 | 2014-02-01 | Erregierre Spa | Processo di preparazione di acido ursodesossicolico ad elevata purezza |
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| CN107531741A (zh) * | 2015-03-10 | 2018-01-02 | 美莱斯股份有限公司 | 氟化和烷基化胆酸 |
| GB201812382D0 (en) * | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 EA EA202191521A patent/EA202191521A1/ru unknown
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/zh active Active
- 2019-12-20 AU AU2019411556A patent/AU2019411556B2/en active Active
- 2019-12-20 KR KR1020217019166A patent/KR102856276B1/ko active Active
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/es unknown
- 2019-12-20 ES ES19831850T patent/ES3036094T3/es active Active
- 2019-12-20 IL IL284093A patent/IL284093B2/en unknown
- 2019-12-20 JP JP2021535715A patent/JP7503063B2/ja active Active
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/pt unknown
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645B1/en active Active
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020128514A1 (en) | 2020-06-25 |
| EP3898645C0 (en) | 2025-06-25 |
| CA3123333A1 (en) | 2020-06-25 |
| MX2021007551A (es) | 2021-10-13 |
| JP7503063B2 (ja) | 2024-06-19 |
| ES3036094T3 (en) | 2025-09-12 |
| GB201820887D0 (en) | 2019-02-06 |
| CN113330020A (zh) | 2021-08-31 |
| EP3898645A1 (en) | 2021-10-27 |
| AU2019411556A1 (en) | 2021-06-10 |
| IL284093B2 (en) | 2025-07-01 |
| IL284093B1 (en) | 2025-03-01 |
| JP2022514401A (ja) | 2022-02-10 |
| BR112021011189A2 (pt) | 2021-08-31 |
| KR102856276B1 (ko) | 2025-09-05 |
| AU2019411556B2 (en) | 2025-04-03 |
| EA202191521A1 (ru) | 2021-09-10 |
| US20220073557A1 (en) | 2022-03-10 |
| CN113330020B (zh) | 2024-04-05 |
| IL284093A (en) | 2021-08-31 |
| EP3898645B1 (en) | 2025-06-25 |
| KR20210125982A (ko) | 2021-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265902A (en) | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases | |
| IL254288B (en) | C22-, c23- and c24-amino-carbonyl-oxy derivatives of bile acids and their use for treating tgr5-mediated diseases | |
| EP3227330A4 (en) | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| IL282361A (en) | Treatment for neurological diseases | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| PL3603621T3 (pl) | Liposomy do leczenia chorób oczu | |
| EP3634394A4 (en) | COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| HUE069820T2 (hu) | Nalfurafin alkalmazása demielinizációs betegségek kezelésére | |
| IL284093A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| IL280441A (en) | Sulfopropanoic acid derivatives for treating neurodegenerative disorders | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3755334A4 (en) | TREATMENT OF LIVER DISEASES | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
| HUE069327T2 (hu) | Neurodegeneratív betegségek megelõzésére vagy kezelésére szolgáló gyógyszer | |
| PL3733684T3 (pl) | Pochodne kwasu ursodeoksycholowego do leczenia wielotorbielowatości | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| EP3534954A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| KR102324922B9 (ko) | 오스테오칼신을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |